What is Recovery Force?
Founded in 2013, Recovery Force operates at the intersection of medical technology and mobile innovation. The company specializes in developing sophisticated solutions designed to enhance circulation, effectively addressing persistent challenges in patient recovery and vascular health. With a comprehensive suite of competencies ranging from intellectual property development and regulatory navigation to clinical validation and commercial distribution, Recovery Force distinguishes itself as a vertically integrated player in the med-tech space.
The firm's market position is defined by its commitment to simplicity and extraordinary outcomes. By focusing on mobile-first medical devices, Recovery Force is actively disrupting traditional healthcare delivery models, providing clinicians and patients with tools that are both accessible and clinically rigorous. Their approach to product development is rooted in deep research and a thorough understanding of the healthcare ecosystem, ensuring that each innovation meets stringent industry standards while delivering tangible improvements in patient health metrics.
How much funding has Recovery Force raised?
Recovery Force has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2019): $10M with participation from Sage Products and Indiana Spine Ventures
Key Investors in Recovery Force
Sage Products
A specialized healthcare company focused on developing and manufacturing innovative products that improve patient outcomes and reduce the risk of hospital-acquired conditions.
Indiana Spine Ventures
A venture capital firm dedicated to supporting early-stage medical technology and healthcare companies that demonstrate significant potential for clinical and commercial impact.
What's next for Recovery Force?
With the successful closure of this major enterprise-level funding, Recovery Force is poised to enter a period of aggressive scaling. The strategic roadmap likely includes the expansion of its distribution networks and the intensification of its clinical validation efforts to support broader market adoption. Furthermore, the company is expected to leverage these resources to refine its product development pipeline, potentially introducing new iterations of its circulation-enhancing technology to a wider demographic of healthcare providers.
As the organization matures, the focus will shift toward solidifying its intellectual property portfolio and enhancing its commercialization capabilities. By maintaining its emphasis on disruptive, simple-to-use medical solutions, Recovery Force is well-equipped to navigate the complexities of the healthcare market, ultimately aiming to set new benchmarks for patient care and vascular health management.
